ClinicalTrials.Veeva

Menu

Stocrin Re-examination Study (0831-028)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status

Completed

Conditions

HIV Infection

Study type

Observational

Funder types

Industry

Identifiers

NCT01065792
2010_008 (Other Identifier)
0831-028

Details and patient eligibility

About

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of STOCRIN through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Enrollment

728 patients

Sex

All

Ages

3+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HIV-1 Infected Patient
  • Patient Who Is Treated With Stocrin 600 Mg Tablet Within Local Label During The Enrollment Period (A Patient Who Changes The Therapy From Stocrin 200 Mg Capsule To Stocrin 600 Mg Tablet Can Be Eligible.)

Exclusion criteria

  • Patient Who Has A Contraindication To Stocrin According To The Local Label

Trial design

728 participants in 1 patient group

1
Description:
Patients with HIV-1 infection taking Stocrin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems